RAPORT ESPI 8/2017 | 22-12-2017 | Zmiana adresu Spółki

Previous PostRAPORT EBI 14/2017 | 27-11-2017 | Rejestracja podwyższenia kapitału zakładowego Spółki oraz rejestracja zmian w składzie Rady NadzorczejNext PostRAPORT ESPI 1/2018 | 09-01-2018 | Zakończenie etapu prac nad projektem PCR|ONE

0Shares

Edocera develops device prototype and confirms its ability to detect signs of stroke

SCOPE FLUIDICS0

30.09.2026

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

SCOPE FLUIDICS0

28.09.2026

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

SCOPE FLUIDICS0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 316 827,10 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Information clause

Whistleblower Protection

RAPORT ESPI 8/2017 | 22-12-2017 | Zmiana adresu Spółki

Related Posts

Edocera develops device prototype and confirms its ability to detect signs of stroke

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations